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Phospholipase D-2 (PLD2) has a key role in breast cancer formation and metastasis formation with PLD small inhibitors reducing primary tumor growth. This study aimed to evaluate
the importance of targeting PLD on the tumor microenvironment. We provide evidence
about the beneficial effect of PLD inhibitors [FIPI (dual PLD1/PLD2) or VU0155072-2 (PLD2
inhibitor)] on avoiding infiltration of tumor-helping macrophages and neutrophils. Tumor
growth and metastasis within the primary tumors had low (<20% over controls) PLD enzyme
activity. Unexpectedly, we found that the inhibitors also affected PLD2 gene expression and
protein albeit at a lesser extent. The later could indicate that targeting both the actual PLD
enzyme and its activity could be beneficial for potential cancer treatments in vivo. F4/80 and
Ly6G staining of macrophages and neutrophils, respectively, and Arg1 staining data were
consistent with M2 and N2 polarization. NOS2 staining increased in xenotransplants upon
treatment with PLD2 inhibitors suggesting the novel observation that an increased recruitment of M1 macrophages occurred in primary tumors. PLD inhibitor-treated primary tumors
had large, fragile, necrotic areas that were Arg1+ for M2 macrophages. The xenotransplants
also caused the formation of large F4/80+ and Ly6G+ (>100 μm) clusters in lungs. However,
PLD inhibitors, particularly FIPI, were able to diminish leukocyte presence. Ex vivo chemotaxis and PLD activity of peripheral blood neutrophils (PMN) and peritoneal macrophages
was also determined. Whereas PMN had impaired functionality, macrophages did not. This
significantly increased (“emboldened”) macrophage function was due to PLD inhibition.
Since tumor-associated leukocytes in primary tumors and metastases were targeted via
PLD inhibition, we posit that these inhibitors have a key role in cancer regression, while still
affording an appropriate inflammatory response at least from off-site innate immunity
macrophages.
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Introduction
Macrophages and neutrophils have been implicated in many studies of human breast cancer
with a growing emphasis currently being placed on the study of inflammatory breast cancer
(IBC), whereby leukocytes isolated from the tumor microenvironment of such patients secrete
cytokines involved in cell movement, which contributes to propagation and metastatic spreading of IBC cells [1,2]. Both macrophages and neutrophils are associated with poor prognosis in
breast cancer studies [3,4]. Neutrophils are recognized as both being inhibitors and promoters
of cancer, as they can eliminate tumor cells disseminated from the main tumor but also prime
the seeding of metastatic cells in the lung. Macrophages and neutrophils that are in the closest
proximity to breast tumors are termed tumor-associated macrophages (TAM) and tumorassociated neutrophils (TAN). TAMs and TANs are further subdivided into M1 (“classical”)
or M2 (“alternatively activated”) macrophages or N1 or N2 neutrophils, respectively, which
represent either anti-tumoral (classified with the number 1) or pro-tumoral (classified with the
number 2) properties dependent upon responses to growth factors, cytokines and chemokines,
as well as proteases [2,5].
The transition from M1 or N1 phenotypes to that of M2 or N2 phenotypes indicates an
overall subcellular change in the tumor microenvironment [2]. Such changes involve a significant switch in the orientation/polarization and differentiation of recruited mononuclear
phagocytes that ultimately commandeer the local innate immune system away from its original
anti-tumor functions to that of a pro-tumor environment [2]. Expression of proteolytic activities in TAMs and TANs from pre-invasive tumors forces the basement membrane to degrade
and breakdown to the point that these types of aggressive tumor cells escape from the initial
tumor and invade into the surrounding stroma and beyond into other tissues [6]. TAMs and
TANs can be detected immunohistochemically using antibodies specific to many different
macrophage- (F4/80 and arginase 1 (Arg1)) or neutrophil-specific (Ly6G) proteins [7–10].
TAMs and TANs secrete growth factors that promote tumor growth and metastasis [11].
Depletion of TANs or TAMs has been shown to slow down tumor growth [4,12–14]. TAMs
secrete various growth factors, e.g. vascular epidermal growth factor (VEGF), platelet-derived
growth factor (PDGF) and transforming growth factor β (TGF-β) [15–17]. TAMs also secrete
epidermal growth factor (EGF) in response to macrophage colony-stimulating factor (MCSF),
which is released by cancer cells and helps them proliferate [18]. Neutrophils are attracted to
the tumor microenvironment by IL-8 that is secreted by human tumor cells [19–21]. Cells in
the tumor microenvironment biologically resemble the functions of inflammation and wound
healing [22,23]. As such, targeting the diverse aspects of the tumor microenvironment during
cancer treatment in association with targeted immune suppression is a significant clinical goal.
Another protein that has a key role in macrophage and neutrophil signaling is phospholipase D (PLD) [24,25]. Several studies have implicated PLD in cancer cell transformation and
progression [26–28]. The isoform phospholipase D2 (PLD2) enhances cell invasion both in
vitro and in vivo, as does the other isoform phospholipase D1 (PLD1) [29–31]. PLD2 positively
influences secretion of chemoattractant IL-8 [19–21,32,33]. Increased phospholipase D expression and increased PLD activity has been documented in human gastric, colorectal, breast,
renal and papillary thyroid cancers [34–38]. Overexpression of lipase-active phospholipase D2
(PLD2) in lymphoma cells was found to be important for tumorigenesis of liver metastases to
occur in vivo, while overexpression of enzymatically-inactive PLD2 hindered liver metastases
[30]. The vascularization of melanoma or lung tumors from phospholipase D1 (PLD1) knockout mice was significantly reduced as a result of PLD downregulation in the tumor environment [29]. Additionally, knockdown of PLD2 in an aggressive cell line of human breast cancer
using short-hairpin RNA (shRNA) specific for PLD2 decreased primary mammary tumor
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growth and lung metastases in a xenotransplanted SCID mouse model [31]. Stable transduction of either PLD1 or PLD2 overexpression in a much less aggressive human breast cancer
cell line boosted tumor growth in a SCID model [31].
There are multiple modes of interaction between PLD and certain of its small molecule
inhibitors, such that different binding sites on PLD2 are in play when PLD2 is bound to irreversible versus partially competitive inhibitors [39]. Such a repertoire of binding sites encompasses both PLD2 catalytic and regulatory regions and suggest mixed inhibition outcomes. PLD
inhibitors delivered to a SCID model were effective in significantly delaying both the onset and
size of primary breast tumors and the number of resulting metastatic axillary tumors [31].
We undertook the current study to ascertain a possible role of PLD in TAMs and TANs.
We report herein that both TAMs and TANs were present in an orthotopic murine model
xenotransplanted with the highly invasive MDA-MB-231 human breast cancer cells. Additionally, we have found further that the tumor promoting effects in leukocytes were abolished via
inhibition of PLD through the use of small-molecule inhibitors specific for PLD, which we
hypothesize indicates that the inflammatory PLD has a key role in breast cancer progression.
This could potentially expand upon important information about the beneficial effects of this
class of inhibitors in breast cancer.

Materials and Methods
Antibodies and reagents
Rabbit anti-PLD2 (H-133) and Mouse anti-Arg1 (E-2) IgG antibodies were from Santa Cruz
Biotechnology (Santa Cruz, CA). Rat anti-mouse F4/80 AlexFluor488 IgG (cat. # MF48020),
rat anti-mouse Ly6G R-PE IgG (cat. # RM3004), Rat anti-mouse IgG2a R-PE isotype control
(cat. # R2B04) and rat anti-mouse IgG2b-FITC isotype control (cat. # R2B01) antibodies were
from Invitrogen (Carlsbad, CA). The F4/80 and Ly6G antibodies positively stain F4/80+ macrophages or predominantly stain Ly6G+ neutrophils (and to a much lesser extent, ~7% of total
signal could be staining for Ly6C+ monocytes), respectively. Mouse anti-PLD2 (SKB2) IgG
antibody was from EMD Millipore (Billerica, MA). Tissue paraffin embedding, sectioning and
mounting and H&E staining were performed by AML Laboratories, Inc. (Baltimore, MD).
EZ-DeWax Solution was from BioGenex (Fremont, CA). Vector hematoxylin nuclear counterstain (Gill’s formulat), VectaMount AQ and VectaShield Mounting media were from Vector
Laboratories (Burlingame, CA). Transwells were from Corning, Inc. (Tewkesbury, MA). Fetal
calf serum was from Gemini Bio-Products (Sacramento, CA). MDA-MB-231 human breast
cancer cells were from ATCC (Manassas, VA). 5-fluoro-2-indolyl des-chlorohalopemide
(FIPI) and N-[2-(4-oxo-1-phenyl-1,3,8-triazaspiro[4,5]dec-8-yl)ethyl]-2-naphthalenecarboxamide (VU0155072-2) were from Cayman Chemical (Ann Arbor, MI) and were used according
to [31,40–42] ([VU0155072-2 has also referred to as “NOPT” [31,40–42]]; Alzet micro-osmotic
pumps were from Durect Corp. (Cupertino, CA).

Animal experiments
All animal procedures and housing occurred in a facility accredited by AAALAC International, and all experimental procedures involving animals were reviewed and approved by
Wright State University’s Institutional Laboratory Animal Care and Use committee. Eight
week old female B- and T lymphocyte-deficient SCID/CB17 mice (C.B117/IcrHsd-PrkdcScid) were purchased from Harlan Laboratories (Indianapolis, IN). Mice were given a week to
acclimate to the animal facility before they were studied. To minimize the risk of any exogenous infection, the SCID mice were maintained and cared for in sterile, static micro-isolation
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cages. Mice received irradiated food (Harlan Teklad 2920X, Harlan Laboratories) and sterile
water ad libitum.

Humane endpoints were in place during the animal study; method of
euthanasia used in the study; and frequency of animal monitoring and
well-being
Regarding the mice to be used for experimental purposes that received xenotransplantation of
human breast cancer cells, the end-point criteria were: (a) body weight loss over 20% due to
lack of proper nourishment; (b) tumor size in excess of 1 cm in 45 days; or (c) ulceration of the
initial mammary tumor greater than 1 cm in diameter. In all 3 cases, any of the animals that
met these criteria would be removed from the study and euthanized by certified personnel at
WSU LAR or by Karen M. Henkels in the PI’s lab (Dr. Julian G. Cambronero). Euthanasia was
performed by CO2 inhalation followed by cervical dislocation. Mice were checked daily by
WSU LAR staff and an additional time each day by the PI’s lab when a pair of investigators
would work together in tandem. Specific signs used to assess animal health, body condition
and overall well-being included: was there evidence that food/water were being consumed or
not and if the animals maintained/gained body weight or not, was the animal well-groomed
with a smooth coat or showing signs of poorly groomed rough coat, was the animal shivering,
was there discharge from the animal eyes, was the animal energetic or lethargic, did the animal
move around in its cage or remain isolated in only one place in the cage, were there any signs
of bleeding or ulceration from the site of the primary tumor or the Alzet pump (see below)
site, did the animal appear to be in pain, etc. Additionally, the size of the primary tumors was
measured on a daily basis using digital calipers, which required that each and every mouse
used in the study was directly handled and its health thoroughly assessed by the pair of investigators from the PI’s lab (Dr. Cambronero). Any animals that failed these criteria were then further assessed by the veterinarian and treated if possible or euthanized if not possible.

Implantation of Alzet miniature osmotic pumps
In experiments studying the effects of PLD inhibitors, Alzet miniature osmotic pumps (Durect
Corp., Cupertino, CA) were used as an inhibitor-delivery system. The pumps were aseptically
filled with either the vehicle (50% DMSO) or inhibitory compound at a concentration that
would deliver 1.8 mg/kg/day of 5-fluoro-2-indolyl des-chlorohalopemide (FIPI) and N-[2(4-oxo-1-phenyl-1,3,8-triazaspiro[4,5]dec-8-yl)ethyl]-2-naphthalenecarboxamide
(VU0155072-2) at a rate of 0.11 μl/hr for 4–5 weeks. For FIPI, this concentration is equivalent
to ~300 nM given a 5.5 h half-life and 18% bioavailability [40], which exerts full inhibition on
PLD2 [41]. For VU0155072-2, the current half-life is not available from the literature, but it
should be sufficient to inhibit PLD2, especially since the IC50 for PLD1 is in the micromolar
range and is much greater than PLD2 [42]. Therefore, 1.8 mg/kg/day for each inhibitor should
yield significant inhibition of PLD or tyrosine kinases. Filled pumps were equilibrated in sterile
0.9% saline at room temp for 18 h to reach steady state and optimal pump performance prior
to implantation. After equilibration, pumps were aseptically implanted subcutaneously on the
left dorsal thoracic area of the SCID mice while under isofluorane anesthesia. Carprofen (5
mg/kg) was administered subcutaneously once for analgesia following surgery.
SCID mice were orthotopically xenotransplanted one day after implantation with 4–6 x 106
cells MDA-MB-231 in sterile HBSS + 0.5% BSA in the left mammary fat pad with the mice
under isoflurane anesthesia. Approximately 4 weeks after injection of cancer cells, mice were
humanely euthanized. The primary breast tumor, lung, any metastatic axillary tumors and
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livers were surgically excised and final dimensions measured. The tissues were then fixed and
stained with hematoxylin and eosin.

Real-time (Quantitative) Reverse Transcription-PCR
Total RNA was isolated from MDA-MB-231 cells with the RNeasy minikit. RNA concentrations were determined by fluorometric assay with the Ribogreen RNA Quantitation Kit, and
samples were normalized to 20 ng/ml RNA. Reverse transcription was performed with 210 ng
of RNA, 210 ng of random hexamers, 500 μM dNTPs, 84 units of RNase OUT and 210 units of
Moloney murine leukemia virus reverse transcriptase and incubated at 42˚C for 55 min. Quantitative PCR reactions were run with 100 ng of total input RNA (5 μl) and 1 μl of the PLD2 gene
expression assay (6-carboxyfluorescein (FAM)-labeled) with the final concentrations being 200
and 400 pmol for the primers and probe, respectively. Sequences for primers and fluorescent
probes, synthesized by Invitrogen, are: PLD1, FAM-5’-ACGAAAAGCACAACAAGGAGTGAGG-3’;
PLD2, FAM-5’-TTGGCCCGGTGGTTTGTGAATGGGG-3’. Quantitative PCR conditions for the
Stratagene Cycler were: 95˚C for 3 min and then 50 cycles of the next 3 steps: 30 s 95˚C, 1 min
60˚C, and then 1 min 72˚C. The “cycle threshold” Ct values were chosen from the linear part of
the PCR amplification curve where an increase in fluorescence can be detected at >10 S.E.
above the background signal. ΔCt was calculated as: ΔCt = Avg. PLD Ct—Avg. Housekeeping
Ct, and gene -fold expression was calculated as 2-(ΔΔCt) = 2-(experimental condition ΔCt—control ΔCt).

PLD activity assay
Samples were processed for PLD2 activity in PC8 liposomes and [3H]n-butanol beginning
with the addition of the following reagents (final concentrations): 3.5 mM PC8 phospholipid,
45 mM HEPES (pH 7.8), and 1.0 μCi [3H]n-butanol in a liposome form, as indicated in [43].
Samples were incubated for 20 min at 30˚C with continuous shaking. Addition of 0.3 ml icecold chloroform/methanol (1:2) stopped the reactions. Lipids were then isolated and resolved
by thin layer chromatography. The amount of [3H]-PBut that co-migrated with PBut standards was measured by scintillation spectrometry.

Immunohistochemical analyses of mouse primary breast tumor, lung
and liver tissues using immunofluorescence staining
Each slide was incubated 2x in BioGenex brand EZ-Dewax solution for 5 min each incubation
and then washed 3x with distilled water. Sections were blocked with 10% FCS, 0.1% Triton X100 in TBS-T for 1 hr. at room temp. Typically, sections were incubated in primary antibody
using 2ml per slide at a 1:200 dilution in blocking buffer for 1 hr. at room temp and were then
washed 3x with PBS for 5 min each wash. Next, sections were incubated in a secondary fluorescently-labeled antibody using 2ml per slide at a 1:200 dilution in blocking buffer for 1 hr. at
room temp and were then also washed 3x with PBS for 5 min each wash. For reference, sections were stained with 1:2000 DAPI for 5 min. at room temp to visualize nuclei in regards to
other cellular components of interest and were rinsed 1x with PBS and then were mounted
using VectaShield Mounting Media. Immunofluorescence microscopy was performed using a
Leica DMI 6000B inverted fluorescent microscope.

Immunohistochemical analyses of mouse primary breast tumor, lung
and liver tissues using DAB chromogen staining
Each slide was incubated 2x in BioGenex brand EZ-Dewax solution for 5 min each incubation
and then washed 3x with distilled water. The HRP-DAB cell and tissue staining kit was used
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from R&D Systems (Minneapolis, MN) to block the sections, incubate with HSS-HRP and to
stain with DAB chromogen per the manufacturer’s quidelines. Typically, following sequential
blocking steps, sections were incubated in biotinylated rat anti-mouse primary antibody
(either F4/80 or Ly6G) using 2ml per slide at a 1:200 dilution in blocking buffer (10% FCS,
0.1% Triton X-100 in TBS-T) for 1 hr at room temp and were then washed 3x with PBS for 15
min each wash. Next, sections were incubated in HSS-HRP from the HRP-DAB cell and tissue
staining kit using 1–3 drops per slide for 30 min at room temp and were then also washed 3x
with PBS for 2 min each wash. Sections were stained with 1–5 drops of DAB chromogen solution from the kit (2 drops DAB per 2 ml of DAB chromogen buffer) for 1 min. Sections were
rinsed with distilled water for 5 min and then counterstain with Vector hematoxylin nuclear
counterstain—Gill formula (Vector Laboratories, Burlingame, CA) for 1 min. Sections were
rinsed with distilled water 3x for 5 min each wash, dipped 10x in acid rinse solution (2 ml glacial acetic acid + 98 ml distilled water), dipped 10x in tap water, incubated for 1 min in bluing
solution (1.5 ml 30% NH4OH + 98.5 ml 70% ethanol) followed by 10 dips in tap water. Sections were mounted using VectaMount AQ Mounting Media. Brightfield microscopy was performed using a Nikon Diaphot inverted microscope.

Quantification of immunofluorescence staining in various tissues
We used ImageJ software to quantify the levels of immunofluorescence staining for the
selected target proteins based on if the tissue was from primary or axillary metastatic tumors
versus lung or liver tissues. These results were quantified using two different criteria. Protein
levels in primary or metastatic axillary tumors were quantified as “total mean target protein
fluorescence” (as total readout of fluorescence intensity in the field of view) in terms of arbitrary units. Alternatively, metastatic burden in the xenotransplanted mouse lungs and livers
were determined by quantifying the area (μm2 x 103) of metastatic “foci” present per field of
view in the various lung and liver sections stained with PLD2, F4/80, Ly6G or Arg1 antibodies.
Using either quantification strategy, triplicate fields were counted per each section and are represented as mean ± SEM. When appropriate, different views of different biological replicates
are shown. In those quantifications the background isotype controls have been subtracted.

Chemotaxis of mouse peritoneal macrophages (MΦ) and peripheral
blood neutrophils (PMN)
Seven to eight ml of peripheral blood from ~10 mice was used to purify PMNs using a Ficoll
gradient. MF were obtained from peritoneal lavage of xenotransplanted mice. Cells were
resuspended at a density of 5 x 105 cells/ml in chemotaxis buffer (DMEM with 0.1% BSA). A
total of 200 μl was placed in the upper chambers (or inserts) of transwell inserts (5 μm pore for
chemotaxis of PMNs or 8 μm pore for MF) that were separated from the lower wells by a 8
mm diameter polycarbonate membrane. Chemoattractants were prepared fresh the day of the
experiment in 1x PBS–0.1% BSA, pH, 7.2, at a stock concentration of 1 μM. When ready for
the assays, chemoattractants were diluted to working concentrations of either 30 nM MCP-1
for MF or 30 nM fMLP for PMNs in 500 μl of chemotaxis buffer and placed into the lower
wells of 24-well plates. Chemotaxis inserts were incubated for 1–3 hr at 37˚C under a 5% CO2
atmosphere. The number of cells that migrated to the lower wells was calculated by counting
four fields in duplicate.

Statistical Analyses
Data presented in the Figs as bars are means + Standard Error of the Mean (SEM) (standard
deviation/n1/2, were n is the sample size). Experiments were performed in technical triplicates
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(for qPCR assays) or technical duplicates (for PLD activity assays) for n = 5 independent
experiments. The difference between means was assessed by the Single Factor Analysis of Variance (ANOVA) test, calculated using SigmaPlot version 10 (Systat Software Inc, San Jose, CA).
Probability of p<0.05 indicates a significant difference. In the Figs, the ( ) symbols above bars
denote statistically significant (P<0.05) ANOVA increases between samples and controls. The
(#) symbols above bars denote statistically significant (P<0.05) ANOVA decreases between
samples and controls. ImageJ quantification of the negative effect of PLD inhibitors on different tissues for immunofluorescence microscopy considered two values: total mean fluorescence of field of view and the total area of positive foci for n = 5 each condition. Data for these
quantifications are presented in the Figs as bars are means + Standard Error of the Mean
(SEM).

Results
Effect of small-molecule PLD inhibitors on PLD2 in breast tumors
following xenotransplantation of human breast cancer cells
In a previous study (31), we have provided in vivo evidence that the PLD2 isoform is fundamental to human breast cancer progression. We wanted to test the ability of PLD activity
inhibitors to affect breast cancer tumor growth and their metastasis, as well as the effect, if any,
on the tumor microenvironment. We chose to deliver PLD inhibitors continually using
micro-osmotic pumps implanted subcutaneously in SCID mice. As summarized in the scheme
presented in Fig 1A and 1B, micro-osmotic pumps were aseptically filled with either the vehicle (50% DMSO) or inhibitory compound at a concentration that would deliver 1.8 mg/kg/day
of the PLD-specific inhibitors 5-fluoro-2-indolyl des-chlorohalopemide (FIPI) and N-[2(4-oxo-1-phenyl-1,3,8-triazaspiro[4,5]dec-8-yl)ethyl]-2-naphthalenecarboxamide
(VU0155072-2) ([VU0155072-2 has also been referred to as “NOPT” [31,40–42]]; at a rate of
0.11 μl/hr for 45 days (Fig 1A and 1B). There are no cytotoxic effects of 750 nM or 7.5 μM FIPI
or 1 μM VU0155072-2 on DNA or protein synthesis of keratinocytes in vitro [44].
Primary and secondary tumors and organs (lungs and livers) were collected and processed
for relevant analyses (Fig 1C). Primary breast tumor sections revealed slight decreases in PLD2
staining in the primary breast tumor tissue sections from the samples that received FIPI or
VU0155072-2 when compared to vehicle-treated samples (Fig 1D), which is quantified in Fig
1E. In secondary axillary tumors (Fig 1F), only FIPI-treatment showed a significant decrease
in PLD staining, which is quantified graphically in Fig 1G. We posit that the detected inhibition on tumor growth and metastasis could be likely due to reduced lipase activity within the
tumors/metastases (Fig 1H–1K). The level of enzyme activity fell to ~20% over controls in primary tumors and to ~55% in axillary tumors (Fig 1H). Unexpectedly, we found that the inhibitors also affected both gene (Fig 1I) and protein expression (Fig 1J and 1K), albeit at a lesser
extent than that of the enzyme activity (~70% levels over controls). This finding was confined
to primary tumors, i.e., no statistical effect in secondary (axillary) tumors for gene expression
(Fig 1I). Therefore, the inhibitors affected PLD activity in vivo and also had a collateral
(smaller) effect on reducing expression levels. The later was not expected and it would indicate
that targeting both the actual enzyme and the activity could be beneficial for potential cancer
treatments in vivo.

Effect on tumor volume and lung metastasis
The lack of PLD activity in the inhibitor-treated samples shown in Fig 1I also affected the volume of the primary tumors, especially 21 days post-transplant and later (Fig 2A). We surmised
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Fig 1. Inhibitory effects of FIPI or VU0155072-2 “NOPT” in mouse mammary tumors following xenotransplantation of human
breast cancer cells. (A-C) SCID mice were xenotransplanted with human MDA-MB-231 breast cancer cells following implantation of
Alzet pumps containing 2 different PLD-small molecule inhibitors of activity: 5-fluoro-2-indolyl des-chlorohalopemide (FIPI) or N- [2- (4oxo- 1- phenyl- 1, 3, 8- triazaspiro[4, 5]dec- 8- yl)ethyl]- 2- naphthalenecarboxamide (VU0155072-2) [also referred to as “NOPT”
[31,40–42]]. Approximately 45 days post xenotransplantation, primary and axillary breast tumors, lungs and livers were harvested from
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mice that received MDA-MB-231 cancer cells and fixed in formalin, which were then embedded in paraffin, sectioned and mounted onto
glass microscope slides. (D,E) Negative effect of small molecule inhibitors on PLD2 in mouse primary mammary and metastatic axillary
tumors. (F,G) Images were quantified in terms of total mean fluorescence per field of view for PLD2 using ImageJ software. (H) PLD
enzyme activity and (I) PLD2 gene expression. (J) PLD2 protein expression and (K) densitometry of same Western blot. Results are
mean relative PLD gene expression (-fold) ± SEM, or mean PLD activity ± SEM, in terms of percent of control (100% = 1,254 ± 117 dpm/
mg protein). Sample sizes were n = 5 for each set of animals used and 6–8 fields were viewed for each section. Statistical analyses for
the increases (*, p<0.05, ANOVA) in xenotransplants and the decreases (#, p<0.05, ANOVA) in PLD inhibitors-treated samples.
doi:10.1371/journal.pone.0166553.g001

that: (i) if PLD2 was crucial to migration of xenotransplanted breast cancer cells from the site
of xenotransplantation into the circulatory system and beyond into other tissues that have
been metastasized (i.e. lungs) and, (ii) if PLD-specific inhibitors reversed this migration, then
we would expect to observe a relative decrease in the levels of PLD2 within such tissue. We
confirmed the presence of PLD2-positive foci in lungs from mice that were xenotransplanted
(Fig 2E–2G) compared to controls (Fig 2B–2D), which is quantified in Fig 2H. PLD2 was
detected throughout the mouse lung as very small punctate foci. We consider this to be the
basal level of PLD2 expression in the mouse lungs and the increased levels of PLD2 expression
observed in the xenotransplanted samples (Fig 2E and 2G) were detected as larger areas of
more profuse staining, which could be indicative of PLD2-containing tumor cells metastasizing to the lungs. Additionally, we observed a significant decrease in the area of PLD2-positive
foci in lungs from xenotransplanted mice that received the PLD inhibitors compared to the
controls.

Tumor-associated macrophage (TAM) F4/80 and tumor-associated
neutrophil (TAN) Ly6G proteins are present in mouse tumors/tissues
following xenotransplantation and are reduced with PLD inhibitors
We next investigated the effect, if any, of PLD inhibitors on the tumor microenvironment with
a specific focus on certain components of the circulatory/inflammatory system that are
affected by PLD signaling, such as macrophages or neutrophils, both of which have been implicated in poor prognosis of breast cancer studies [3,4]. We found tumor-associated macrophages (TAM) and tumor-associated neutrophils (TAN) that were positive for F4/80 (a
macrophage-restricted cell surface glycoprotein) (Fig 3A and 3B) and LY6G antibodies (a myeloid differentiation antigen that is predominantly expressed in neutrophils and to a much
lesser extent in monocytes) (Fig 3C and 3D). Importantly, there was a significant decrease in
the total mean fluorescence of F4/80 and Ly6G staining in primary mammary tumors. This
decrease was larger in Ly6G-stained tissues (possible from TAN-specific staining) (~40%) (Fig
3D) than in F4/80-stained tissues (possible from TAM-specific staining, which is confirmed in
subsequent figures) (~25%) (Fig 3B) and in either case, the decrease in accumulation of leukocytes was larger than the decrease in immunofluorescence area afforded by the inhibitors (Fig
2A). These data indicate that PLD inhibitors have a double effect: one that acts directly on
tumor growth and another that is more pronounced that inhibits the accumulation of TAMs
and TANs in the microenvironment.
We next used IF staining specific for either mouse tumor-associated macrophages using a
α-F4/80 antibody (Fig 4) or for mouse tumor-associated neutrophils using a α-Ly6G antibody
(Fig 5). Xenotransplants caused the appearance of small (10–30) μm “punctae” and large
(>100 μm) clusters (Figs 4B, 4B’, 5B and 5B’; compared to non-xenotranplats (Figs 4A, 4A’,
5A and 5A’). At present, we do not know the nature of these clusters, but suspect they could be
due to metastases as well as non-specific cross-reactivity of nerve bundles in addition to large
macrophage (Fig 4) or neutrophil (Fig 5) accumulations. Interestingly, lung slices probed with
fluorophore-relevant isotype controls (Figs 4E or 5E) did not show the presence of those
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Fig 2. PLD inhibitors decrease PLD2 expression in foci of lungs following xenotransplantation. (A) Primary tumor
volume from xenotransplanted mice in the presence or absence (“control” = vehicle only) of PLD inhibitors delivered by
Alzet pumps, as in Fig 1 legend. (B-D) Lung sections from non-xenographed controls. (B) PLD2-FITC staining only. (C)
DAPI staining only and (D) the merged PLD2-FITC+DAPI staining. (E-G) Lung tissues from xenotransplanted mice. (E)
Xenotransplanted controls with Alzet pumps delivering vehicle. (F) Xenotransplanted with Alzet pumps delivering vehicle
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FIPI or (G) VU0155072-2. Scale bar = 200 μm. (H) ImageJ quantification of the negative effect of PLD inhibitors on total
mean fluorescence of the total area of PLD2 positive foci in lung tissues in terms of μm2 x 103. Sample sizes were n = 5 for
each set of animals used and 6–8 fields were viewed for each section. Statistical analyses for the increases (*, p<0.05,
ANOVA) in xenotransplants and the decreases (#, p<0.05, ANOVA) in PLD inhibitors-treated samples.
doi:10.1371/journal.pone.0166553.g002

clusters, indicating that indeed, staining from the clusters in 4B,B’ is derived in large part from
F4/80+ macrophages and in 5B,B’ are derived in large part from Ly6G+ neutrophils.
Moving now to the effect of PLD inhibitors, we found that in lung sections, there were
fewer and smaller F4/80-stained “punctae” and “clusters” in FIPI- and VU0155072-2-treated
samples (Fig 4C, 4D, 4C’ and 4D’) compared to vehicle (DMSO) alone, and a similar pattern
for neutrophils was also found (Fig 5C, 5D, 5C’ and 5D’). This was quantified as foci area (Fig
4I) for F4/80+ macrophages and (Fig 5I) for Ly6G+ neutrophils; as well as total fluorescence in
each field of view (Fig 4J) for F4/80+ macrophages and (Fig 5J) for Ly6G+ neutrophils. In either
case there is decrease in cell staining of ~30–50% in xenotransplanted mice that received PLD
inhibitors, particularly FIPI, indicating that the PLD inhibitors were able to diminish leukocytes associated to lung metastasis.
Taking all of this into consideration from the data presented in Figs 3–5, these results reinforce the importance of small-molecule inhibitors in reducing the presence of tumor-associated macrophages and neutrophils in tissues where breast cancer could invade and metastasize
in vivo.

Fig 3. Presence of tumor-associated macrophage (TAM) F4/80 and tumor-associated neutrophil (TAN) Ly6G in xenotransplanted mice are
suppressed by PLD inhibitors. (A,C) Immunofluorescence staining of mouse primary breast tumor sections using either a rat anti-mouse F4/80
AlexaFluor 488 IgG antibody specific for TAMs (A) or a rat anti-mouse Ly6G-R-PE IgG antibody specific for TANs (C). Each set of three panels represents
results from Xenotransplanted MDA-MB-231 cells in the presence of vehicle, FIPI or VU0155072-2, respectively. Scale bar = 200 μm. (B,D) ImageJ
quantification of the negative effect of PLD inhibitors on the total mean fluorescence of each field of view for either F4/80 (B) or Ly6G (D) in primary
metastatic breast tumors. Sample sizes were n = 5 for each set of animals used and 6–8 fields were viewed for each section. Statistical analyses for the
increases (*, p<0.05, ANOVA) in xenotransplants and the decreases (#, p<0.05, ANOVA) in PLD inhibitors-treated samples.
doi:10.1371/journal.pone.0166553.g003
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Fig 4. Decreased F4/80+ macrophages in the presence of PLD inhibitors using IF microscopy of lung sections. Lung sections from MDA-MB-231
xenotransplanted mice were incubated with a FITC-F4/80 IgG antibody specific for TAMs (A-D) or biological duplicates from independent experiments (A’D’) or with an isotype control-FITC IgG antibody (E-H). (A,A’,E) Tissues from non-xenographed controls; (B,B’,F) from Xenotransplanted controls with
Alzet pumps delivering vehicle; (C,C’,G) Xenotransplanted with Alzet pumps delivering vehicle FIPI or (D,D’,H) VU0155072-2. Scale bar = 200 μm.
ImageJ quantification on the total area of positive foci for TAM using F4/80 staining (I) in lung tissues in terms of μm2 x 103. Also, total mean fluorescence
of each field of view is presented in panel (J). In both those quantifications the background isotype controls have been subtracted. Sample sizes were n = 5
for each set of animals used and 6–8 fields were viewed for each section. Statistical analyses for the increases (*, p<0.05, ANOVA) in xenotransplants and
the decreases (#, p<0.05, ANOVA) in PLD inhibitors-treated samples.
doi:10.1371/journal.pone.0166553.g004

The M2 macrophage protein Arg1 is present in mouse mammary tumors
following xenotransplantation of human breast cancer cells
TAMs promote tumorigenesis within the tumor microenvironment [45–47]. Arginine 1
(Arg1) is associated with M2 macrophage and N2 neutrophil polarization [2,10,48,49]. We
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Fig 5. Decreased Ly6G+ neutrophils in the presence of PLD inhibitors using IF microscopy of lung sections. Lung sections from MDA-MB-231
xenotransplanted mice were incubated with a TRITC-Ly6G antibody specific for TANs (A-D) or biological duplicates from independent experiments
stained with Ly6G-R-PE (A’-D’) TANs (A-D) or biological duplicates from independent experiments stained with Ly6G-R-PE or with an isotype controlR-PE IgG antibody (E-H). (A,A’,E) Tissues from non-xenographed controls; (B,B’,F) from Xenotransplanted controls with Alzet pumps delivering vehicle;
(C,C’,G) Xenotransplanted with Alzet pumps delivering vehicle FIPI or (D,D’,H) VU0155072-2. Scale bar = 200 μm. ImageJ quantification on the total area
of positive foci for TANs using Ly6G staining (I) in lung tissues in terms of μm2 x 103. Also, total mean fluorescence of each field of view is presented in
panel (J). In both those quantifications the background isotype controls have been subtracted. The use of TRITC- or R-PE labeling yielded virtually similar
results. Sample sizes were n = 5 for each set of animals used and 6–8 fields were viewed for each section. Statistical analyses for the increases (*,
p<0.05, ANOVA) in xenotransplants and the decreases (#, p<0.05, ANOVA) in PLD inhibitors-treated samples.
doi:10.1371/journal.pone.0166553.g005

determined if Arg1 was present in the primary or metastatic tumors in the xenotransplantation
model. As shown in Fig 6, Arg1 was present in primary mammary tumors (Fig 6A and 6B)
and metastatic axillary tumors (Fig 6C and 6D). Immunofluorescent staining from mice that
had received PLD inhibitors was reduced when compared to xenotransplant+vehicle only
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Fig 6. Induction of the M2 macrophage protein Arg1 in xenotransplanted mouse mammary tumors. (A-B) Mouse primary breast tumors. (C-D)
metastatic axillary tumors. (E-G) Lungs showing xenotransplant vs. no-xenotransplant controls. Sections showing Arg1 expression. Nuclei were stained
with DAPI for reference. Scale bars = 200 μm. (B,D,F) Quantification of the negative effect of PLD inhibitors on Arg1 staining. Sample sizes were n = 5 for
each set of animals used and 6–8 fields were viewed for each section. Statistical analyses for the increases (*, p<0.05, ANOVA) in xenotransplants and
the decreases (#, p<0.05, ANOVA) in PLD inhibitors-treated samples. (H-I) Presence of Arg1 in necrotic areas in xenotransplanted primary tumors. A
boundary of non-necrotic versus necrotic cells within the primary tumors is delineated by the white, dashed line in the FIPI-treated sample (I).
doi:10.1371/journal.pone.0166553.g006
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samples. Although the data presented in Figs 4 and 5 using F4/80 and Ly6G staining are not
necessarily specific for M2 macrophages or N2 neutrophils, the results shown in Fig 6 using
staining of Arg1 are consistent for M2 macrophages or N2 neutrophils. Additionally, nonxenotransplanted mice generated absolutely no breast cancer-derived tumors under our experimental conditions. Consequently, there are no tissue sections of primary or secondary tumors
available to include in this figure.
However, such analysis was performed for the lung sections, as non-xenotransplanted mice
still had 2 lungs that could be metastasized. As such, we found that Arg1 (Fig 6E–6G) was similarly detected in lung tissue of xenotransplanted mice and then significantly decreased in both
total Arg1 IF area and mean Arg1 fluorescence as a result of treatment with the PLD inhibitors.
We also found that PLD-specific inhibitor-treated tumors had large, fragile, necrotic areas that
were Arg1+ with M2 macrophages (Fig 6H and 6I). The presence of necrotic areas in PLD-specific inhibitor-treated samples (Fig 6I) was clearly more readily evident than in controls (Fig
6H). This could likely be due to the infiltration of Arg1+ M2-type macrophages to the sight of
inflammation surrounding/within the tumor with the purpose of cleaning the inflamed site or
to initiate resolution of the inflammation.

Expression of NOS2 in primary breast tumors
Arginine 1 (Arg1) (associated with M2 macrophages and N2 neutrophils) metabolizes L-arginine to L-ornithine and urea and is in direct competition with nitrogen synthase 2 (NOS2).
NOS2 is associated with M1 macrophages and is upregulated in the tumor microenvironment
of TAMs and TANs and during tumor progression [50,51]. We found very little staining for
NOS2 (Fig 7). Approximately, 1–2 positive findings every 6–8 fields studied was detected in
primary tumor sections (red-stained spots). However, whether animals received inhibitor
treatment or not resulted in obvious differences (Fig 7A vs. 7B and 7D), even though such
examples of the rarity of these findings are presented. Data from Figs 6 and 7 suggest that Arg1
but not NOS2 was induced in primary and metastatic tumors and that Arg1 was then negatively affected by the presence of the PLD small-molecule inhibitors, which suggests that the
presence of a TAM response could be involved in a non-classical immune response in this
human breast cancer formation/metastasis model. In addition, the increased NOS staining in
xenotransplanted mice upon treatment with PLD inhibitor (Fig 7) may suggest that these
inhibitors increased recruitment of M1 macrophages to the tumor microenvironment.
These data suggest a shift in macrophage polarization from M2 to that of the less invasive
and anti-tumoral M1 macrophage in the PLD-specific inhibitor-treated samples. Additionally,
the use of PLD inhibitors could be a means to recruit M1 macrophages to the tumor microenvironment, which could yield a more favorable outcome in terms of patient health.

The hepatic cellular environment changes concomitantly with
tumorigenesis that is decreased by PLD inhibitors
As Arg1 is significantly expressed in the liver in general and as our previous results indicate
the significance of Arg1 in tumor metastasis to lung tissue of the model, we next determined if
there was an effect of PLD inhibitors on liver Arg1 in samples from our model. Using hematoxylin and eosin staining of liver tissue sections from our mouse models, we noted no significant lesions in livers from mice that were not xenotransplanted (Fig 8A), but we did observe
the presence of very mild multifocal perivascular lymphocyte and neutrophil aggregates in
mice that were xenotransplanted only (Fig 8B).
Additionally, in the livers from xenotransplanted mice in the presence of PLD inhibitors,
we observed improved liver appearance based upon the presence of small clusters of round
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Fig 7. Lack of NOS2 induction in xenotransplanted mouse mammary tumors. (A-D) Primary breast tumor sections were
incubated with rabbit anti-NOS2 IgG antibody followed by goat anti-rabbit IgG TRITC antibody and DAPI for reference. (A)
Xenotransplanted MDA-MB-231 cells, vehicle. (B Xenotransplanted MDA-MB-231 cells, FIPI. (C) Xenotransplanted MDA-MB-231
cells, VU0155072-2. Scale bar = 100 μm. Sample sizes were n = 5 for each set of animals used and 6–8 fields were viewed for
each section. (D) Quantification of NOS2 from IF images shown in (A-C). Statistical analyses for the increases (*, p<0.05, ANOVA)
in xenotransplants and the decreases (#, p<0.05, ANOVA) in PLD inhibitors-treated samples.
doi:10.1371/journal.pone.0166553.g007

cells with moderate cytoplasm randomly scattered throughout the parenchyma that included a
few areas of granulopoiesis in the parenchyma (Fig 8C and 8D). The H&E data suggest a
changing environment within the hepatic parenchyma of mice that were xenotransplanted
with human breast cancer perhaps as a result of an underlying immune response that coincides
with tumorigenesis. This change in hepatic cellular environment was also noted with a large
increase in the amount of Arg1 localized to the liver of xenotransplant only samples compared
to non-xenotransplanted samples (Fig 8E–8H), which was significantly reduced in the presence of FIPI or VU0155072-2 (Fig 8I). Similar results were also observed for F4/80 and LY6G
staining in liver tissues (Fig 8J–8Q).

Effect of PLD inhibitors on the gene expression of selected cytokines
Tumor-related tissues in xenotransplanted mice also experienced early stages of an inflammatory/immune response that coincided with severity of tumorigenesis. A possible mechanism
would be an effect of the PLD inhibitors (through reducing the amount of PA available) on
gene expression, as PA is a mitogen. We have shown previously [31] that these cells changed
invasive phenotype, as shPLD2-MDA-MB-231 cells are less invasive than the parental
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Fig 8. The hepatic cellular environment is altered with PLD inhibitors. Liver sections were incubated with hematoxylin and eosin (A-D) or
antibodies specific for Arg1 (E-H), F4/80 (J-M) or LY6G (N-Q) for immunofluorescence microscopy. Xenotransplanted MDA-MB-231 cells in
the presence of vehicle, FIPI or VU0155072-2, respectively, and no xenotransplantation in the presence of vehicle. (A-D) Scale bar = 50 μm.
(E-Q) Scale bar = 200 μm. (I) ImageJ quantification of the negative effect of PLD inhibitors on the total area of Arg1 positive foci in liver tissues
in terms of μm2 x 103. Sample sizes were n = 5 for each set of animals used and 6–8 fields were viewed for each section. Statistical analyses
for the increases (*, p<0.05, ANOVA) in xenotransplants and the decreases (#, p<0.05, ANOVA) in PLD inhibitors-treated samples.
doi:10.1371/journal.pone.0166553.g008
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MDA-MB-231 cells and O/E-PLD2-MCF-7 cells are much more invasive than the parental
MCF-7 cells, both of which again highlight the key role of PLD in cancer cell invasiveness. We
hypothesize that the level of specific cytokines could be altered in breast cancer cells following
treatment with those inhibitors. Fig 9A indicates results of experiments using several human
breast cancer cells lines prior to xenotransplantation. As shown in Fig 9A, PLD2, GM-CSF, IL8 and Rac2 (which is important for cell chemotaxis and metastasis [52]) were significantly
increased in PLD2-overexpressing MCF-7 cells and significantly decreased in PLD2-silenced
MDA-MB-231 cells. Human mammary epithelial cells (HMEC) were used as negative control
cells. These data indicate that altering PLD gene expression in low- or high-aggressive breast
cancer sets the stage for altering expression of other genes vital to cell chemotaxis and metastasis, the effects of which could be compounded following xenotransplantation into an orthotopic model.

PLD inhibitors, which target both TAN and TAM in the tumor
microenvironment, “spare” innate immune system functionality of nontumor-associated macrophages (peritoneal Mø)
Lastly, we wanted to investigate if the innate immune cells of the mice were affected by the
PLD inhibitor treatments in addition to the herein proven effect on the TAMs and TANs.
Using chemoattractant-mediated chemotaxis as a physiological measure of leukocyte function
ex vivo from peripheral blood polymorphonuclear leukocytes (PMNs,) as well as peritoneal
macrophages (MF), we found that vehicle-treated PMNs responded positively to fMLP stimulation in SCID mice (Fig 9B). However, chemotaxis was significantly decreased in both the
FIPI- and VU0155072-2-treated animals (Fig 9B). Vehicle-treated peritoneal MF also
responded positively to MCP-1 stimulation (Fig 9D).
Surprisingly, peritoneal MF from inhibitor-treated animals were resistant to chemotaxis
inhibition (Fig 9D); in fact, a slight activation effect was observed, indicating that these cells
were “emboldened” in their physiological response to chemoattractants (Fig 9D). These data
suggest the initial inflammatory response of both PMNs and peritoneal MF during chemotaxis
remained intact in these SCID animals. However, we found that PMNs were targeted to both
PLD inhibitors, while peritoneal MF were resistant to both of the PLD inhibitors. The chemotaxis data also broadly coincided with PLD enzymatic activity (Fig 9C and 9E).
Data from Fig 9 emphasizes that the innate inflammatory response, as measured by chemotaxis is intact and PLD inhibitors could have a side effect by affecting functionality of peripheral neutrophils without impacting functionality of peritoneal macrophages, which are
different from TAMs, the target we have proved to be affected by the inhibitors.

Discussion
The signaling protein phospholipase D (PLD) is central to cell migration. It is involved in both
leukocyte chemotaxis and cancer cell invasion. Using a well-controlled in vivo study of human
breast cancer xenotransplanted into SCID mice and subsequent molecular biology, enzymology and pathology analyses, the data presented herein provides evidence that PLD2 expression
is important to tumor-associated macrophages in human breast cancer growth and cell
migration.
We recently showed that the signaling enzyme PLD2 is present in breast tumors, and mice
injected with lowly invasive MCF-7 cells overexpressing PLD2 developed tumors more readily,
whereas mice injected with highly invasive MDA-MB-231 cells that were stably silenced for
PLD2 appeared as negative controls [31]. Since the tumor promoting effects in these immune
cells were abolished upon inhibition of the enzyme phospholipase D, this indicates that this
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Fig 9. Differential effects of PLD small-molecule inhibitors on mouse leukocyte chemotaxis. (A) Gene
expression by quantitative PCR of MCF-7 cells stably overexpressing (O/E) PLD2 (O/E-PLD2-MCF7) or
MDA-MB-231 stably silenced with shRNA for PLD2 (shPLD2-MB-MB-231). Non-cancerous control cells,
HMEC (human mammary epithelial cells). (B-E) Functional assay of non-tumor associated leukocytes.
Peripheral blood PMNs (B,C) or peritoneal macrophages (D,E) from mice treated with either vehicle, FIPI or
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VU0155072-2 were used for chemotaxis assays (B,D) and PLD activity assays (C,E) in response to either 30
nM IL-8 (for PMNs) or 30 nM MCP-1 (for macrophages). For chemotaxis, the numbers of cells that migrated to
the lower were calculated by counting four fields in duplicate. Triplicate results are mean ± SEM and are
expressed in terms of either number of cell migrated per field or number of invading cells per insert. For PLD
assay, the amount of TLC-isolated [3H]-PBut that co-migrated with PBut standards was measured by
scintillation spectrometry. Results are mean ± SEM and are expressed in terms of percent of control.
Statistical analyses for the increases (*, p<0.05, ANOVA) in xenotransplants and the decreases (#, p<0.05,
ANOVA) in PLD inhibitors-treated samples.
doi:10.1371/journal.pone.0166553.g009

PLD from the immune cells, which functioned as part of an inflammatory response/process,
also has a key role in breast cancer progression. Overexpressing PLD resulted in larger mammary and axillary tumors, faster tumor onset and more lung metastases [31]. Conversely,
silencing the PLD2 gene in cancer cells or implanting mice with micro-osmotic (Alzet) pumps
containing the PLD small-molecule inhibitors FIPI and VU0155072-2 resulted in smaller
tumors and fewer lung metastases [31].
Data from this present study indicates that although PLD2 gene expression in breast cancer
was not affected by small-molecule inhibitor treatment, its protein expression was reduced
after such treatment, which also negatively impacted PLD2 lipase activity. Along with tumorrelated issues, xenotransplanted mice also experienced early stages of an inflammatory/
immune response that coincided with the severity of tumorigenesis. In the context of tumor
progression, the loss of immune cells like TAMs or TANs coincided with alteration in tumor
growth and hampered the next step, which was metastasis.
To our surprise, we found that the FIPI and VU0155072-2 PLD inhibitors also inhibited
leukocyte (TAM and TAN) recruitment to the tumors, which suggests a shift in macrophage
polarization occurred from M2 to that of the less invasive and anti-tumoral M1 macrophage in
the PLD-specific inhibitor-treated samples. Additionally, the use of PLD inhibitors could be a
means to recruit M1 macrophages to the tumor microenvironment, which could yield a more
favorable outcome in terms of patient health.
The Ly6G antibody we used for this study for Figs 3 and 5 is the RB6-8C5 clone and has
the potential to react with both Ly6G+ and Ly6C+ cells, although the specificity for Ly6C is
much weaker. Ly6C+-containing cells include monocytes that are mobilized from the bone
marrow and the spleen and recruited to cancer cell-targeted tissues, such as the lungs. The
positive reactivity for Ly6G staining in our xenotransplanted lung samples (Fig 5) suggests
that a small portion of these cells that we consider to be neutrophilic could in fact be monocytic. Monocytes in SCID mice range from ~4–7%, which is dependent upon gender with
females having slightly more monocytes than males [53]. Therefore, the potential exists that
up to 7% of the Ly6G staining we detected in xenotransplanted mouse lungs could instead
be monocytic Ly6C protein. Further, a recent study has documented preferential accumulation of Ly6G+ neutrophils versus Ly6C+ monocytes in lungs of a mouse model that closely
mimics human breast cancer [54], which we feel supports our data that indicates we
detected Ly6G+ neutrophils in xenotransplanted SCID mouse lungs well beyond that of
Ly6C+ monocytes.
In SCID mice, the acquired immune system (which includes both B- and T-cells) is compromised but not the compartment of innate immune system (which includes the complement
and natural killer cells). As the SCID mouse strain is known to be “leaky” as a function of time,
resident macrophages of SCID mice could be phenotypically and functionally altered to a
M2-like phenotype and that M1 and M2 macrophages could be selectively induced [55–57].
Our data shows a decreased involvement of F4/80-, Arg1- and Ly6G-mediated pathways in
our orthotopic breast cancer xenograft model as a result of PLD-specific inhibitor treatment.
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Conclusions
Data from this current study indicates that primary breast tumors increased in both tumor volume and metastases as a function of time and that PLD-specific inhibitors decreased both of
these factors, which strongly suggests PLD2 has a role in breast tumor progression. This work
and an earlier study [31] demonstrates that PLD inhibitors decrease breast cancer tumor
growth and reduce the appearance of TAMs and TANs infiltrated in the tumor microenvironment, indicating a potential therapeutic value for these molecules. For the mechanism, the
decrease of TAMs and TANs could be derived from the diminished presence in tumor tissues
of cytokines GM-CSF and IL-8, as well as a decreased gene expression of the small GTPase
Rac2, key for leukocyte chemotaxis. Another novel finding uncovered in this study is while
PLD inhibitors affected the functionality of non-tumor associated neutrophils (peripheral
blood PMN), they did not inhibit peritoneal macrophages, indicating that at least some part of
the innate immune system is still operative even in the presence of effective tumor-decreasing
PLD inhibitors.
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